All questions
Safety: Xtandi (enzalutamide) in castration-resistant prostate cancer 4 questions · 1 source
Safety questions that apply to every indication of Xtandi are on Xtandi (enzalutamide), all indications: Safety .
Side effects What are the side effects of Xtandi in nonmetastatic CRPC (PROSPER)? Applies to Non-metastatic castration-resistant prostate cancer (PROSPER)
“Overall, 32 patients (3.4%) receiving XTANDI died from adverse reactions. The reasons for death with ≥ 2 patients
included coronary artery disorders (n = 7), sudden death (n = 2), cardiac arrhythmias (n = 2), general physical health
deterioration (n = 2), stroke (n = 2), and secondary malignancy (n = 5; one each of acute myeloid leukemia, brain
neoplasm, mesothelioma, small cell lung cancer, and malignant neoplasm of unknown primary site). Three patients
(0.6%) receiving placebo died from adverse reactions of cardiac arrest (n = 1), left ventricular failure (n = 1), and
pancreatic carcinoma (n = 1). Grade 3 or higher adverse reactions were reported among 31% of XTANDI-treated patients
and 23% of placebo-treated patients. Discontinuations with an adverse reaction as the primary reason were reported for
9% of XTANDI-treated patients and 6% of placebo-treated patients. Of these, the most common adverse reaction leading
to treatment discontinuation was fatigue, which occurred in 1.6% of the XTANDI-treated patients compared to none of
the placebo-treated patients. Table 4 shows adverse reactions reported in PROSPER that occurred at a ≥ 2% higher
frequency in the XTANDI arm than in the placebo arm.” (opens the source at this quote in a new tab) Copy Flag
Note: Each table row lists XTANDI Grade 1-4, XTANDI Grade 3-4, comparator Grade 1-4, and comparator Grade 3-4 percentages, in that order, as in the table header. The comparator is placebo.
What are the side effects of Xtandi in chemotherapy-naive metastatic CRPC (PREVAIL)? Applies to Chemotherapy-naive metastatic castration-resistant prostate cancer (PREVAIL)
“Table 2. Adverse Reactions in PREVAIL
XTANDI
(N = 871)
Placebo
(N = 844)
Grade 1-41
(%)
Grade 3-4
(%)
Grade 1-4
(%)
Grade 3-4
(%)
General Disorders
Asthenic Conditions2
47
3.4
33
2.8
Peripheral Edema
12
0.2
8
0.4
Musculoskeletal and Connective Tissue Disorders
Back Pain
29
2
22
3
Arthralgia
21
1.6
16
1.1
Gastrointestinal Disorders
Constipation
23
0.7
17
0.4
Diarrhea
17
0.3
14
0.4
Vascular Disorders
Hot Flush
18
0.1
8
0
Hypertension
14
7
4.1
2.3
Nervous System Disorders
Dizziness3
11
0.3
7
0
Headache
11
0.2
7
0.4
Dysgeusia
8
0.1
3.7
0
Mental Impairment Disorders4
6
0
1.3
0.1
Restless Legs Syndrome
2.1
0.1
0.4
0
Respiratory Disorders
Dyspnea5
11
0.6
8
0.6
Infections and Infestations
Upper Respiratory Tract Infection6
16
0
11
0
Lower Respiratory Tract And Lung Infection7
8
1.5
4.7
1.1
Psychiatric Disorders
Insomnia
8
0.1
6
0
Renal and Urinary Disorders
Hematuria
9
1.3
6
1.3
Injury, Poisoning and Procedural Complications
Fall
13
1.6
5
0.7
Non-Pathological Fracture
9
2.1
3
1.1
Metabolism and Nutrition Disorders
Decreased Appetite
19
0.3
16
0.7
Investigations
Weight Decreased
12
0.8
8
0.2
Reproductive System and Breast Disorders
Gynecomastia
3.4
0
1.4
0
1.
CTCAE v 4.
2.
Includes asthenia and fatigue.
3.
Includes dizziness and vertigo.
4.
Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention.
5.
Includes dyspnea, exertional dyspnea, and dyspnea at rest.
6.
Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis.
7.
Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection.” (opens the source at this quote in a new tab) Copy Flag
Note: Each table row lists XTANDI Grade 1-4, XTANDI Grade 3-4, comparator Grade 1-4, and comparator Grade 3-4 percentages, in that order, as in the table header. The comparator is placebo.
What are the side effects of Xtandi after docetaxel in metastatic CRPC (AFFIRM)? Applies to Metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy (AFFIRM)
“XTANDI
(N = 800)
Placebo
(N = 399)
Grade 1-41
(%)
Grade 3-4
(%)
Grade 1-4
(%)
Grade 3-4
(%)
Nervous System Disorders
Headache
12
0.9
5
0
Dizziness3
9
0.5
7
0.5
Spinal Cord Compression and Cauda Equina
Syndrome
7
7
4.5
3.8
Paresthesia
7
0
4.5
0
Mental Impairment Disorders4
4.3
0.3
1.8
0
Hypoesthesia
4
0.3
1.8
0
Infections and Infestations
Upper Respiratory Tract Infection5
11
0
6
0.3
Lower Respiratory Tract and Lung Infection6
8
2.4
4.8
1.3
Psychiatric Disorders
Insomnia
9
0
6
0.5
Anxiety
6
0.3
4
0
Renal and Urinary Disorders
Hematuria
7
1.8
4.5
1
Pollakiuria
4.8
0
2.5
0
Injury, Poisoning and Procedural Complications
Fall
4.6
0.3
1.3
0
Non-pathologic Fractures
4
1.4
0.8
0.3
Skin and Subcutaneous Tissue Disorders
Pruritus
3.8
0
1.3
0
Dry Skin
3.5
0
1.3
0
Respiratory Disorders
Epistaxis
3.3
0.1
1.3
0.3
1.
CTCAE v 4.
2.
Includes asthenia and fatigue.
3.
Includes dizziness and vertigo.
4.
Includes amnesia, memory impairment, cognitive disorder, and disturbance in attention.
5.
Includes nasopharyngitis, upper respiratory tract infection, sinusitis, rhinitis, pharyngitis, and laryngitis.
6.
Includes pneumonia, lower respiratory tract infection, bronchitis, and lung infection.” (opens the source at this quote in a new tab) Copy Flag
Note: Each table row lists XTANDI Grade 1-4, XTANDI Grade 3-4, comparator Grade 1-4, and comparator Grade 3-4 percentages, in that order, as in the table header. The comparator is placebo. Table 1 continues from page 5 to page 6 of the Prescribing Information, where its header repeats.
Xtandi vs bicalutamide: how did side effects compare in TERRAIN? Applies to Chemotherapy-naive metastatic castration-resistant prostate cancer, compared with bicalutamide (TERRAIN)
Note: Each table row lists XTANDI Grade 1-4, XTANDI Grade 3-4, comparator Grade 1-4, and comparator Grade 3-4 percentages, in that order, as in the table header. The comparator is bicalutamide.